Global private equity and venture capital news and research

Aerie’s venture backers eye strong stake valuations from imminent IPO $

22 Oct 2013

The venture capital-backers of eye disease treatment company Aerie Pharmaceuticals all plan to drop their stakes to below 20 per cent through the company’s impending IPO.

Sorry, to get access to this you need to subscribe for free.

In order to view more content, sign-up to our free daily newsletter.

If you would like to read the premium stories, have complete access to our breaking news and Limited Partner magazine you need to become a Premium Subscriber.

Subscribe to AltAssets today

Login to AltAssets

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016